{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:45Z","timestamp":1789676265898,"version":"4.0.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1097\/ftd.0000000000000100","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T13:43:54Z","timestamp":1400161434000},"page":"76-83","source":"Crossref","is-referenced-by-count":33,"title":["Population Pharmacokinetics of Valproic Acid in Adult Chinese Epileptic Patients and its Application in an Individualized Dosage Regimen"],"prefix":"10.1097","volume":"37","author":[{"given":"Wei-wei","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-lian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-lai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-fang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xian-zhong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00007691-199704000-00006","article-title":"Pharmacokinetics of valproic acid in patients with juvenile myoclonic epilepsy on monotherapy.","volume":"19","author":"Sundqvist","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2125.1998.00769.x","article-title":"Therapeutic drug monitoringantiepileptic drugs.","volume":"46","author":"Eadie","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1006\/phrs.1998.0424","article-title":". Spotlight on the continual applicability of routine plasma monitoring antiepileptic drugs in the treatment of epilepsy.","volume":"39","author":"El Desoky","year":"1999","journal-title":"Pharmacol Res"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2165\/00003088-198611050-00004","article-title":"Population pharmacokinetics. Theory and clinical application.","volume":"11","author":"Whiting","year":"1986","journal-title":"Clin Pharmacokinet"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/j.1552-4604.1995.tb04020.x","article-title":"A model for estimating individualized valproate clearance values in children.","volume":"35","author":"Botha","year":"1995","journal-title":"J Clin Pharmacol"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1002\/j.1552-4604.1997.tb04301.x","article-title":". Population-based investigation of valproic acid relative clearance using nonlinear mixed effects modeling: influence of drug-drug interaction and patient characteristics.","volume":"37","author":"Yukawa","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/(SICI)1099-081X(199907)20:5<233::AID-BDD179>3.0.CO;2-5","article-title":". Population estimation of valproic acid clearance in adult patients using routine clinical pharmacokinetic data.","volume":"20","author":"Blanco-Serrano","year":"1999","journal-title":"Biopharm Drug Dispos"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1365-2710.1999.00202.x","article-title":". Valproate population pharmacokinetics in children.","volume":"24","author":"Serrano","year":"1999","journal-title":"J Clin Pharm Ther"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1046\/j.1365-2710.2002.00440.x","article-title":". Population pharmacokinetics of intravenous valproic acid in Korean patients.","volume":"27","author":"Park","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1046\/j.1365-2710.2003.00528.x","article-title":". Pharmacoepidemiologic investigation of a clonazepam-valproic acid interaction by mixed effect modeling using routine clinical pharmacokinetic data in Japanese patients.","volume":"28","author":"Yukawa","year":"2003","journal-title":"J Clin Pharm Ther"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00228-003-0699-7","article-title":". Pharmacokinetic modelling of valproic acid from routine clinical data in Egyptian epileptic patients.","volume":"59","author":"EL Desoky","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/bdd.636","article-title":"Population pharmacokinetics of valproate in Mexican children with epilepsy.","volume":"29","author":"Correa","year":"2008","journal-title":"Biopharm Drug Dispos"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":". Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling.","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/01.mjt.0000155113.89092.58","article-title":"Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.","volume":"13","author":"Panomvana Na Ayudhya","year":"2006","journal-title":"Am J Ther"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effects in NONMEM.","volume":"28","author":"Wahlby","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020254823597","article-title":". Assessment of type I error rates for the statistical sub-model in NONMEM.","volume":"29","author":"Wahlby","year":"2002","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","article-title":"Evaluating pharmacokineticpharmacodynamic models using the posterior predictive check.","volume":"28","author":"Yano","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","article-title":"Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects.","volume":"20","author":"Mandema","year":"1992","journal-title":"J Pharmacokinet Biopharm"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/j.1552-4604.1997.tb04326.x","article-title":"Stability and performance of a population pharmacokinetic model.","volume":"37","author":"Ette","year":"1997","journal-title":"J Clin Pharmacol"},{"key":"R20-11-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1007\/s11095-006-9067-5","article-title":". Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.","volume":"23","author":"Brendel","year":"2006","journal-title":"Pharm Res"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cmpb.2007.12.002","article-title":"Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R.","volume":"90","author":"Comets","year":"2008","journal-title":"Comput Methods Programs Biomed"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00007691-200306000-00005","article-title":". Population pharmacokinetics of carbamazepine in Chinese epilepsy patients.","volume":"25","author":"Jiao","year":"2003","journal-title":"Ther Drug Monit"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"29","DOI":"10.7748\/paed.11.9.29.s24","article-title":"Epilepsy education in schools.","volume":"11","author":"Coleman","year":"1999","journal-title":"Paediatr Nurs"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2710.2010.01215.x","article-title":". Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy.","volume":"36","author":"Bondareva","year":"2011","journal-title":"J Clin Pharm Ther"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF01059771","article-title":". Effect of misspecification of the absorption process on subsequent parameter estimation in population analysis.","volume":"21","author":"Wade","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/FTD.0b013e31826aabc3","article-title":"Safe and effective variability-a criterion for dose individualization.","volume":"34","author":"Holford","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.116","article-title":". Valproic acid clearance: unbound fraction and diurnal variation in young and elderly adults.","volume":"37","author":"Bauer","year":"1985","journal-title":"Clin Pharmacol Ther"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00007691-199202000-00009","article-title":". Binding parameters of valproic acid to serum protein in healthy adults at steady state.","volume":"14","author":"Kodama","year":"1992","journal-title":"Ther Drug Monit"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00007691-199704000-00003","article-title":". Carbamazepine population pharmacokinetics in children: mixed-effect models.","volume":"19","author":"Delgado Iribarnegaray","year":"1997","journal-title":"Ther Drug Monit"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S1474-4422(03)00483-6","article-title":"Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs.","volume":"2","author":"Patsalos","year":"2003","journal-title":"Lancet Neurol"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.eplepsyres.2006.04.002","article-title":". The influence of old age and enzyme inducing comedication on the pharmacokinetics of valproic acid at steady-state: a case-matched evaluation based on therapeutic drug monitoring data.","volume":"70","author":"Fattore","year":"2006","journal-title":"Epilepsy Res"},{"key":"R33-11-20210129","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1097\/FTD.0b013e31811f3296","article-title":". Population pharmacokinetics of valproic acid concentrations in elderly nursing home residents.","volume":"29","author":"Birnbaum","year":"2007","journal-title":"Ther Drug Monit"},{"key":"R34-11-20210129","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1248\/yakushi.124.443","article-title":"Influence of coadministered antiepileptic drugs on serum antiepileptic drug concentrations in epileptic patients -quantitative analysis based on suitable transforming factor in Japanese.","volume":"124","author":"Fukuoka","year":"2004","journal-title":"Yakugaku Zasshi"},{"key":"R35-11-20210129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.1990.tb03610.x","article-title":". The effects of phenytoin and carbamazepine on serum concentrations of mono-unsaturated metabolites of valproic acid.","volume":"29","author":"Kondo","year":"1990","journal-title":"Br J Clin Pharmacol"},{"key":"R36-11-20210129","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00007691-198512000-00004","article-title":"Serum concentrations of valproic acid: influence of dose and comedication.","volume":"7","author":"May","year":"1985","journal-title":"Ther Drug Monit"},{"key":"R37-11-20210129","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-2008-1059589","article-title":"Serum concentrations and enzyme induction in epileptic children treated with phenytoin and valproate.","volume":"13","author":"de Wolff","year":"1982","journal-title":"Neuropediatrics"},{"key":"R38-11-20210129","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2165\/00003088-199631060-00005","article-title":". Pharmacokinetic interactions between antiepileptic drugs. Clinical considerations.","volume":"31","author":"Riva","year":"1996","journal-title":"Clin Pharmacokinet"},{"key":"R39-11-20210129","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FTD.0b013e31820f40f8","article-title":". Optimal sampling strategy development methodology using maximum a posteriori Bayesian estimation.","volume":"33","author":"van der Meer","year":"2011","journal-title":"Ther Drug Monit"},{"key":"R40-11-20210129","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.yebeh.2007.03.009","article-title":". Evaluation of an epilepsy education program for Grade 5 students: a cluster randomized trial.","volume":"10","author":"Martiniuk","year":"2007","journal-title":"Epilepsy Behav"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000100","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:28:37Z","timestamp":1620952117000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201502000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000100","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}